Finance
Italian drug maker Recordati boosts 2025 core profit, revenue forecast
Published by Global Banking & Finance Review®
Posted on February 13, 2025
1 min readLast updated: January 26, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on February 13, 2025
1 min readLast updated: January 26, 2026
Recordati raises 2025 profit forecast to €970M-€1B and revenue to €2.60B-€2.67B, citing growth in rare disease products.
(Reuters) - Italian drug maker Recordati raised on Thursday its core profit (EBITDA) forecast to a range between 970 million euros and 1 billion euros ($1.01-$1.04 billion) with an around 37.5% EBITDA margin, from previous guidance at around 37%.
The pharmaceutical firm's 2025 revenue forecast has also improved to a range of 2.60 billion euros to 2.67 billion euros from a previous indication of above 2.4 billion euros, as it sees a double-digit growth across all metrics, boosted by its rare disease products.
The Milan-based company posted a 12.5% jump in its full-year earnings before interest, tax, depreciation and amortisation to 865.8 million euros, while its revenue rose 12.4% to 2.34 billion euros.
Recordati said it will publish an updated three-year plan on April 29, along with medium-term financial targets.
($1 = 0.9602 euros)
(Reporting by Romolo Tosiani in Gdansk; Editing by Tomasz Janowski)
The main topic is Recordati's increased 2025 profit and revenue forecasts.
Recordati's new EBITDA forecast is between €970 million and €1 billion.
Recordati's growth is driven by its rare disease products.
Explore more articles in the Finance category
